ERBB2 and breast cancer: Neoadjuvant targeted therapy has become the most effective treatment modality for locally advanced BC and inflammatory BC, as well as the preferred treatment modality for the majority of stage II and III triple-negative BC (TNBC) and HER2-positive BC cases (28).